Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB–IIC melanoma in the United States

Key Points

• This analysis estimates the cost-effectiveness of adjuvant nivolumab in patients with resected stage IIB–IIC melanoma.
• Utilized a conservative recurrence-focused framework for evaluation.
• Assessed health outcomes against costs of nivolumab treatment over a short-term horizon.
• Nivolumab improves health outcomes but is unlikely to be cost-effective at current prices.

Abstract